John Noles, MD
Pain Medicine · Bossier City, LANPI 1417937012
Payments from drug & device makers
Across 949 payments — averaging $2021.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1.9M
- GRT US Holding, Inc.$4K
- AbbVie$813
- Stimwave Technologies Incorporated$475
- Medtronic$432
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$407
- plus $2K from 27 others
Across 2 payments — averaging $37.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$76
What the payments were for
- Food & beverage$7,498100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 663 | $1,909,665 |
| GRT US Holding, Inc. | 2 | $4,050 |
| AbbVie(2 entities) | 94 | $813 |
| Stimwave Technologies Incorporated | 3 | $475 |
| Medtronic(2 entities) | 47 | $432 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $407 |
| Nevro Corp. | 8 | $384 |
| Pfizer | 18 | $280 |
| Amgen(2 entities) | 20 | $257 |
| Abbott | 9 | $239 |
| Collegium Pharmaceutical, Inc. | 13 | $200 |
| Biohaven Pharmaceuticals, Inc. | 4 | $119 |
| Vertos Medical, Inc. | 4 | $110 |
| Saluda Medical Americas, Inc. | 5 | $107 |
| Curonix LLC | 1 | $98 |
| Averitas Pharma Inc. | 4 | $94 |
| Scilex Pharmaceuticals Inc. | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $49 |
| Biodelivery Sciences International, Inc. | 3 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Vertical Pharmaceuticals, LLC | 2 | $32 |
| AstraZeneca | 2 | $31 |
| Pacira Therapeutics, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $23 |
| Novartis | 1 | $20 |
| Shionogi Inc | 1 | $20 |
| Nalu Medical, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Avanos Medical | 1 | $14 |
| Baudax Bio Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,918,201 in reported general payments places this provider in the 95th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 151 | $126,517 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,264 | $62,830 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,102 | $61,562 |
| Buprenorphine | 264 | $57,991 |
| Xtampza ErOxycodone Myristate | 56 | $48,549 |
| OxycontinOxycodone Hcl | 42 | $33,454 |
| Gabapentin | 1,667 | $19,804 |
| Pregabalin | 1,097 | $16,432 |
| MovantikNaloxegol Oxalate | 34 | $15,235 |
| Morphine Sulfate ErMorphine Sulfate | 474 | $14,542 |
| Tramadol Hcl ErTramadol Hcl | 188 | $13,692 |
| Fentanyl | 84 | $11,031 |
| Oxycodone Hcl | 379 | $7,949 |
| Tramadol Hcl | 1,310 | $7,631 |
| Tizanidine Hcl | 744 | $5,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $200 | $175,066207 claims |
| Redhill Biopharma Inc.Movantik | $23 | $15,23534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 pain medicine providers in Louisiana.
Other pain medicine in Bossier City
- David HirschBossier City$5K
- Russell StuermannBossier City$5K
- Yashar EshraghiNew Orleans$357K
- Gassan ChaibanLake Charles$297K
- Thomas MyersMandeville$173K
- Alan KayeNew Orleans$78K
- Derrick DeanTerrytown$68K
- Hazem EissaNew Orleans$50K
- Robert OwensNew Orleans$47K
- Nathan HarrisonCovington$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.